Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 29
---
 incur immediate dilution of $0.93 per share, representing the difference between the assumed public offering price of $2.00 per share, which is the last reported sale price of our Common Stock on the Nasdaq Global Market on February 3, 2025, and our pro forma net tangible book value as of September 30, 2024, which information as of September 30, 2024 gives retroactive effect to the 1 for 100 ratio of our Reverse Stock Split. For more information on the dilution you may suffer as a result of investing in this offering, see “Dilution.” Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. We have not specified a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during or after the offering. Risks Related to our Business and Industry We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. We are a preclinical stage biopharmaceutical company with a limited operating history, and we have incurred significant net losses since our inception in 2016. We incurred net losses of approximately $7.3 million and $11.8 million for the years ended December 31, 2023 and 2022, respectively. Additionally, we incurred a net loss of approximately $8.4 million for the nine-month period ended September 30, 2024. As of September 30, 2024, we had an accumulated deficit of $71.6 million. We have funded our operations to date primarily with proceeds from the sale of our equity securities in private financing transactions. We have no products approved for commercial sale and we are devoting, and expect to continue devoting, substantially